SVB Leerink Maintains Outperform on Eliem Therapeutics, Lowers Price Target to $4
SVB Leerink analyst Marc Goodman maintains Eliem Therapeutics (NASDAQ:ELYM) with a Outperform and lowers the price target from $9 to $4.
Eliem Therapeutics Q2 EPS $(0.56) Up From $(3.11) YoY
Eliem Therapeutics (NASDAQ:ELYM) reported quarterly losses of $(0.56) per share. This is a 81.99 percent increase over losses of $(3.11) per share from the same period last year.
Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary
Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and…
Recap of Monday’s Biotech Catalysts – End of the Day Summary
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.
Eliem Announces Updated Development Plans And The Advancement Of ETX-155 For The Treatment Of Major Depressive Disorder
Initiating a Phase 1 pharmacokinetics trial of ETX-155 to enable a Phase 2a trial in MDD planned to commence in first quarter of 2023
Sufficient capital expected to fund operations until mid-2024
SVB Leerink Maintains Outperform Rating for Eliem Therapeutics: Here’s What You Need To Know
SVB Leerink has decided to maintain its Outperform rating of Eliem Therapeutics (NASDAQ:ELYM) and lower its price target from $13.00 to $9.00.
Shares of Eliem Therapeutics are trading down 4.04% over the last 24 hours, at $3.56 per share.
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics’ Tebipenem, Graybug Reviews Strategic Alternatives
Here's a roundup of top developments in the biotech space over the last 24 hours:
Eliem Concludes Patient Enrolment In Mid-Stage Study Of Radicular Back Pain Drug
Eliem Therapeutics (NASDAQ: ELYM) has completed dosing of the last patient in its Phase 2a trial of ETX-810 in patients with chronic lumbosacral radicular pain (LSRP).
5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.